Body fat patterning in polycystic ovary syndrome women as a predictor of the response to clomiphene.
BACKGROUND
To investigate the difference in the response to clomiphene citrate (CC) based on body fat distribution in women with polycystic ovary syndrome (PCOS).


METHODS
Ninety anovulatory PCOS women were divided into two subgroups based on treatment response: women who ovulated with CC (CC responders, n = 49) and those who did not ovulate with CC (CC nonresponders, n = 41). Baseline characteristics included age, age at menarche, height, weight and body mass index [BMI; weight/(height)2]. Percentage of body fat, body fat mass and the ratio of trunk fat to leg fat mass amount (trunk-leg fat ratio) were measured by dual-energy X-ray absorptiometry (DEXA).


RESULTS
Age, age at menarche and height did not differ between the two groups. However, trunk-leg fat ratio in CC responders (0.9 +/- 0.4) was significantly lower than that in CC nonresponders (1.3 +/- 0.4) (p < 0.001). Percentage of body fat, body fat mass and BMI were also lower in CC responders (p < 0.01). On multiple regression analysis, however, trunk-leg fat ratio proved to be a superior predictor of CC responder to percentage of body fat, BMI or body fat mass (standardized regression coefficient > or = 0.510; t-values > or = 3.432; p < 0.001).


CONCLUSIONS
Response to CC in anovulatory PCOS women differs with body fat distribution.
Douchi
Tsutomu
T
Department of Obstetrics and Gynecology, Faculty of Medicine, Kagoshima University, Kagoshima, Japan.
Oki
Toshimichi
T
Yamasaki
Hideki
H
Nakae
Mitsuhiro
M
Imabayashi
Akiko
A
Nagata
Yukihiro
Y
D000273:Adipose Tissue / Q000503:physiopathology*; D000328:Adult; D001823:Body Composition; D015992:Body Mass Index; D002996:Clomiphene / Q000008:administration & dosage*; D015331:Cohort Studies; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016015:Logistic Models; D009765:Obesity / Q000175:diagnosis / Q000209:etiology* / Q000503:physiopathology*; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D011237:Predictive Value of Tests; D011336:Probability; D011446:Prospective Studies; D018570:Risk Assessment; D012720:Severity of Illness Index; D013739:Testosterone / Q000097:blood; D016896:Treatment Outcome
D002996:Clomiphene; D013739:Testosterone